Protara Therapeutics
TARA
28 hedge funds and large institutions have $12.5M invested in Protara Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
12% more funds holding
Funds holding: 25 → 28 (+3)
0.03% more ownership
Funds ownership: 1.06% → 1.09% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less capital invested
Capital invested by funds: $13.2M → $12.5M (-$658K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$135K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$79.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55.2K |
| 5 |
BlackRock
New York
|
+$49.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$170K |
| 2 |
PPCM
Pillar Pacific Capital Management
Pacifica,
California
|
-$21K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6.13K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.01K |
TARA Hedge Fund Activity: Q1 2017 in Review
28 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2017, worth a combined $12.5M — down 5% from $13.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TARA positions and 1 closed out — a net gain of 6 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $135K. The largest seller was Baker Bros. Advisors, cutting an estimated $170K.
- 28 institutional investors held Protara Therapeutics (TARA) as of Q1 2017, up from 25 in Q4 2016.
- Funds reported $12.5M of Protara Therapeutics stock for Q1 2017, down 5% quarter-over-quarter.
- 7 funds opened new Protara Therapeutics positions in Q1 2017 and 1 closed out, a net change of +6 holders.
- The largest Protara Therapeutics buyer in Q1 2017 was Jacobs Levy Equity Management, an estimated $135K added.
- The largest Protara Therapeutics seller in Q1 2017 was Baker Bros. Advisors, an estimated $170K sold.
Based on aggregated 13F filings for Q1 2017.